CTOs on the Move

Sera Prognostics

www.seraprognostics.com

 
Sera Prognostics is a leading proteomic and bioinformatics company dedicated to improving the lives of women and babies through precision biomarker-based tests designed to enhance pregnancy care. Sera’s vision is to deliver pivotal information in early pregnancy to physicians, to help them to improve the health of their patients and reduce costs of healthcare delivery. Sera’s PreTRM® Test reports to a physician the individualized risk of a pregnant woman to deliver prematurely, enabling earlier proactive interventions in patients with higher risk. Rigorous clinical validation of PreTRM® Test performance (accuracy of predicting premature delivery) was reported in the American Journal of ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Robert Harrison
Chief Information Officer Profile

Funding

Sera Prognostics raised $36M on 11/13/2019
Sera Prognostics raised $100M on 04/28/2021

Similar Companies

Southern Research Institute

Southern Research Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carmell Therapeutics

Our groundbreaking plasma-based materials are designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures.

Cadence Neuroscience

Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.

Creative Biogene.Inc

Creative Biogene.Inc is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dren Bio

Dren Bio is a San Carlos, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.